Species |
Human |
Protein Construction |
FGL1 (Leu23-Ile312) Accession # Q08830 |
hFc |
N-term |
C-term |
|
Purity |
> 95% as analyzed by SDS-PAGE |
Endotoxin Level |
< 1 EU/μg of protein by gel clotting method |
Biological Activity |
Immobilized h_LAG3 at 5.0 μg/ml (100 μl/well) can bind FGL1, hFc, Human with a linear range of 0.097–50 μg/ml when detected by Mouse Anti-Human IgG Fc-HRP. |
Expression System |
HEK 293 |
Apparent Molecular Weight |
~61.8 kDa, on SDS-PAGE under reducing conditions. |
Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
Immobilized h_LAG3 at 5 μg/ml (100 μl/well) can bind FGL1 Fc Chimera, Human with a linear range of 0.097–50 μg/ml when detected by Mouse Anti-Human IgG Fc-HRP. Background was subtracted from data points before curve fitting.
Target Background |
FGL1 (Fibrinogen-like protein 1), also known as hepatocyte-derived fibrinogen-related protein 1 (HFREP-1), HP-041, hepassocin (HPS), and liver fibrinogen-related protein 1 (LFIRE-1), is a liver-specific secreted protein belonging to the fibrinogen superfamily whose members share a fibrinogen domain at their C-termini. FGL1 is an immune suppressive molecule that inhibits the activation of antigen-specific T cells by acting as a major ligand of LAG3, and binds LAG3 independently of MHC class II. |
Synonyms |
HFREP-1; HP-041; HPS; LFIRE-1 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.